Volume 11, Issue 4, Pages (April 2012)

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Volume 376, Issue 9753, Pages (November 2010)

Volume 16, Issue 7, Pages (July 2017)

Volume 370, Issue 9586, Pages (August 2007)

Volume 386, Issue 10006, Pages (November 2015)

Allergic diseases and the effect of inhaled epinephrine in children with acute bronchiolitis: follow-up from the randomised, controlled, double-blind,

Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of.

Volume 355, Issue 9212, Pages (April 2000)

Volume 379, Issue 9824, Pages (April 2012)

Volume 357, Issue 9273, Pages (June 2001)

Volume 367, Issue 9517, Pages (April 2006)

Pharmacogenetics and future drug development and delivery

Volume 376, Issue 9747, Pages (October 2010)

Volume 16, Issue 9, Pages (September 2015)

Volume 388, Issue 10058, Pages (November 2016)

Volume 378, Issue 9785, Pages (July 2011)

Volume 376, Issue 9734, Pages (July 2010)

Neonatal vitamin A: time to move on?

Demographic and practice factors predicting repeated non-attendance in primary care: a national retrospective cohort analysis David A Ellis, PhD, Ross.

Volume 369, Issue 9563, Pages (March 2007)

Meta-analysis of randomised controlled trials

Volume 5, Issue 4, Pages (April 2006)

Volume 389, Issue 10076, Pages (April 2017)

Intraoperative radiotherapy for early breast cancer

Volume 371, Issue 9611, Pages (February 2008)

Volume 376, Issue 9734, Pages (July 2010)

Volume 13, Issue 3, Pages (March 2012)

Volume 15, Issue 8, Pages (July 2014)

Volume 366, Issue 9486, Pages (August 2005)

Volume 14, Issue 4, Pages (April 2015)

Volume 12, Issue 9, Pages (September 2013)

Volume 373, Issue 9677, Pages (May 2009)

Aspirin in the prevention of cancer – Author's reply

Volume 14, Issue 12, Pages (December 2015)

Volume 374, Issue 9707, Pages (December 2009)

Volume 9, Issue 9, Pages (September 2008)

Volume 373, Issue 9663, Pages (February 2009)

Volume 372, Issue 9642, Pages (September 2008)

Volume 365, Issue 9466, Pages (April 2005)

Volume 9, Issue 10, Pages (October 2008)

Meta-analysis of randomised controlled trials

Volume 375, Issue 9732, Pages (June 2010)

Resuscitation at birth and cognition at 8 years of age: a cohort study

Volume 381, Issue 9875, Pages (April 2013)

Volume 378, Issue 9785, Pages (July 2011)

Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double- blind, parallel-group, placebo-controlled trial Dr Andrew R Goudie,

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled.

Volume 9, Issue 9, Pages (September 2008)

Volume 12, Issue 8, Pages (August 2013)

Volume 388, Issue 10056, Pages (October 2016)

Volume 376, Issue 9753, Pages (November 2010)

Volume 388, Issue 10058, Pages (November 2016)

Volume 371, Issue 9627, Pages (May 2008)

Volume 9, Issue 4, Pages (April 2008)

Volume 373, Issue 9658, Pages (January 2009)

Department of Error The Lancet Volume 369, Issue 9564, (March 2007)

Low-technology approaches

Volume 373, Issue 9658, Pages (January 2009)

Volume 375, Issue 9719, Pages (March 2010)

Volume 375, Issue 9714, Pages (February 2010)

Volume 11, Issue 3, Pages (March 2010)

Volume 373, Issue 9672, Pages (April 2009)

Volume 376, Issue 9747, Pages (October 2010)

Volume 13, Issue 7, Pages (July 2014)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup:

Volume 8, Issue 10, Pages (October 2009)

Volume 14, Issue 7, Pages (June 2013)

Volume 371, Issue 9611, Pages (February 2008)

Volume 20, Issue 8, Pages (August 2019)

Presentation transcript:

Volume 11, Issue 4, Pages 331-340 (April 2012) Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial Laura Bonnett, MmathStat, Catrin Tudur Smith, PhD, David Smith, MD, Paula Williamson, PhD, Prof David Chadwick, MD, Prof Anthony G Marson, MD The Lancet Neurology Volume 11, Issue 4, Pages 331-340 (April 2012) DOI: 10.1016/S1474-4422(12)70018-2 Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile *Patients with a time from first seizure to randomisation in the first or last 1% of the variable were removed from the data set.21 † Patients with generalised epilepsy were removed from analyses. The Lancet Neurology 2012 11, 331-340DOI: (10.1016/S1474-4422(12)70018-2) Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 2 Combination of risk factors for time to treatment failure Bars show 95% CIs. M=male. F=female. The Lancet Neurology 2012 11, 331-340DOI: (10.1016/S1474-4422(12)70018-2) Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 3 Relative hazard ratio plots for age and total number of seizures before randomisation for the time to treatment failure Hazard ratio estimates with 95% CIs are shown for overall time to treatment failure, for age (A) and total number of seizures (B), and for time to treatment failure because of inadequate seizure control and because of unacceptable adverse events, for age (C) and total number of seizures (D). The Lancet Neurology 2012 11, 331-340DOI: (10.1016/S1474-4422(12)70018-2) Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 4 Relative hazard ratio plots for age, time from first seizure to randomisation, and total number of seizures for time to 12 months of remission Hazard ratio estimates with 95% CIs are shown for time to 12 months of remission, for age (A), time from first seizure (B), and total number of seizures (C). The Lancet Neurology 2012 11, 331-340DOI: (10.1016/S1474-4422(12)70018-2) Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 5 Combination of risk factors for time to 12 months of remission Bars show 95% CIs. M=male. F=female. The Lancet Neurology 2012 11, 331-340DOI: (10.1016/S1474-4422(12)70018-2) Copyright © 2012 Elsevier Ltd Terms and Conditions